China Looks Ahead on AI Medtech With New Guidelines, Collaboration

ARTICLE SUMMARY:

Getting new artificial intelligence technologies through China regulators is by no means going to be easy, but the National Medical Products Administration is working with other experts in the country to lay a policy groundwork for the sector, including recently finalized guidelines for “deep learning” AI devices.

China is taking steps to fill gaps in its regulatory framework for AI-based medical technology.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite

Questions?

We're here to help! Please contact us at: